Search 

Aspect Biosystems uses proprietary bioprinting and cell culture technologies to create high quality living 3D human tissues.  We aim to improve the pre-clinical drug discovery process by providing pharmaceutical companies and researchers with functional living tissues that better predict the human response to drugs.  Our testing platforms will enable pharmaceutical customers to identify failed drugs earlier in the development pipeline, before expensive clinical trials begin.  Aspect Biosystem’s long-term vision is to create human tissues on demand for multiple applications including cosmetics-testing, personalized medicine, diagnostics and regenerative medicine.

Immusoft’s mission is to develop a breakthrough platform for delivering targeted medicines — programming a patient’s own cells to become miniature drug factories.

Our technology instructs a patient's cells to constantly secrete gene-encoded medicines (biologics). It will enable new treatments by solving current delivery limitations and production challenges. We are initially targeting orphaned diseases. 

Immusoft’s platform can program cells to continually produce and secrete therapeutic proteins and rare antibodies that have been impossible to elicit with a vaccine. This approach makes possible treatments that are otherwise impractical due to short halflife, injection site reactions, production challenges or a small market size. It offers many of the benefits of traditional approaches and modern gene therapies with less risk and greater control.

Immusoft has received grants from the National Institutes of Health and Peter Thiel's Breakout Labs as well as support from private investors, including the former head of preclinical development at Seattle Genetics. We have an exclusive license option on our core technology from Caltech and have filed two additional patents covering our extensive modifications to the technology.

ISP technology could replace a lifetime of infusions with a patient’s own drug-producing cells.

Precision NanoSystems Inc. (“PNI”) has developed proprietary technology (NanoAssemblr) and companion Reagent Kits (SUB9KITS) that enable the simple manufacture of novel nanoparticles that are used to delivery genetic and small molecule medicines (nanomedicines). Nanomedicines are the "FedEx" of the health-care industry and are used for cell-specific delivery of research tools, diagnostic imaging agents and drugs to study, diagnose and treat disease. PNI's products are commercialized and in high demand from many of leading RNA and small molecule therapeutic biotechnology and pharmaceutical companies.  http://www.precisionnanosystems.com/products/

For more than 35 years STRATEC Biomedical AG is a business partner for the development and manufacture of fully automated analyzer systems. It's headquarter is located in Birkenfeld, Germany and it has nearly 500 employees in 5 locations worldwide. The public owned company has cooperations with 15 of the 20 IVD companies worldwide and has boosted its annual sales from USD 10.4 million in 1998 (IPO) to USD 122.4 million in 2014. STRATEC has strived to achieve market-leading expertise and to build a technology pool that is unique to its industry. The company invests in a variety of fields within the diagnostic and life science sector including medical devices.